An interventional study of Lung volume reduction surgery with endobronchial valve implantation in Chronic Obstructive Pulmonary Disease, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital — 16 open to participants now, 17 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · China-Japan Friendship Hospital.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 8 that started in 2023, is one of 13 with no phase, reaches primary completion later than 16 of the 16 other live ones, and was the 9th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →16 of the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:
China-Japan Friendship Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 40+
China-Japan Friendship Hospital · Sites in China
Ages 40–85
China-Japan Friendship Hospital · Sites in China
Ages 18–55
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 8 started in 2023.
This study's planned enrollment of 100 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 360 across the 13 interventional studies, 1,500 across the 11 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.
1 of the studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07097896China-Japan Friendship HospitalEndobronchial Silicone Valve for Patients With Emphysema | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this type of study: clinical trial is to evaluate the effect of bronchial valve implantation on cardiac function and skeletal muscle function in Chronic Obstructive Pulmonary Disease. The main question it aims to answer are:evaluate the effect of bronchial valve implantation on cardiac function and skeletal muscle function.
Participants will undergo Lung volume reduction surgery with endobronchial valve implantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Lung volume reduction surgery with endobronchial valve implantation
the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
Baseline ventricular volume
cardiac magnetic resonance imaging
Time frame: Baseline
Ventricular volume (6 months after surgery)
cardiac magnetic resonance imaging
Time frame: 6 months after surgery
Ventricular volume(12 months after surgery)
cardiac magnetic resonance imaging
Time frame: 12 months after surgery
Baseline FEV1
Pulmonary function tests
Time frame: Baseline
FEV1 (6 months after surgery)
Pulmonary function tests
Time frame: 6 months after surgery
FEV1(12 months after surgery)
Pulmonary function tests
Time frame: 12 months after surgery
Baseline left Ventricular Ejection Fractions
Echocardiography
Time frame: Baseline
Left Ventricular Ejection Fractions (6 months after surgery)
Echocardiography
Time frame: 6 months after surgery
Left Ventricular Ejection Fractions (12 months after surgery)
Echocardiography
Time frame: 12 months after surgery
Baseline exercise tolerance
6-minute walk test
Time frame: Baseline
Exercise tolerance (6 months after surgery)
6-minute walk test
Time frame: 6 months after surgery
Exercise tolerance (12 months after surgery)
6-minute walk test
Time frame: 12 months after surgery
Baseline health impairment and quality of life of patients Baseline health impairment and quality of life of patients
St. George's Respiratory Questionnaire
Time frame: Baseline
Health impairment and quality of life of patients (6 months after surgery)
St. George's Respiratory Questionnaire
Time frame: 6 months after surgery
Health impairment and quality of life of patients (12 months after surgery)
St. George's Respiratory Questionnaire
Time frame: 12 months after surgery
Baseline cross sectional area of rectus femoris
Rectus femoris ultrasound
Time frame: Baseline
Cross sectional area of rectus femoris (6 months after surgery)
Rectus femoris ultrasound
Time frame: 6 months after surgery
Cross sectional area of rectus femoris (12 months after surgery)
Rectus femoris ultrasound
Time frame: 12 months after surgery
Baseline mmuscle strength of lower limb
Myometer
Time frame: Baseline
Mmuscle strength of lower limb (6 months after surgery)
Myometer
Time frame: 6 months after surgery
Mmuscle strength of lower limb (12 months after surgery)
Myometer
Time frame: 12 months after surgery
Started Mar 2023 (actual). Primary completion is estimated for Dec 2028, 69 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 69 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2024 → Dec 2028 and completion Dec 2024 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
China-Japan Friendship Hospital →